Trademark, Harrison Street to Break Ground on $135M Anthem Redevelopment in Arlington, Texas
Why this matters
The planned $135 million redevelopment of a 43-year-old asset in Arlington by a joint venture between Trademark Property Co. and Harrison Street underscores several institutional trends in US commercial real estate. First, it signals continued appetite among fund managers and institutional operators for value-add repositioning strategies, particularly in secondary markets with strong demographic and economic fundamentals. Arlington’s proximity to the Dallas-Fort Worth metroplex, combined with its evolving urban profile, makes it a target for capital seeking growth beyond gateway cities. Second, the scale and timing of this redevelopment suggest confidence in the availability of construction financing amid a tightening lending environment. While debt markets have become more selective, sponsors with established track records and joint venture structures appear better positioned to secure capital for projects that enhance asset quality and income potential. Finally, this transaction reflects a broader institutional pivot towards redevelopment over ground-up development, as investors seek to mitigate entitlement and cost risks while capitalizing on existing site infrastructure. For allocators, the deal exemplifies how private equity and fund capital continue to chase repositioning opportunities that align with evolving tenant demand and market repositioning in Sun Belt metros.
Editorial analysis · AI-assisted
ARLINGTON, TEXAS — A joint venture between Trademark Property Co. and Harrison Street Asset Management is scheduled to break ground Monday, Aug. 3 on Anthem, a $135 million redevelopment of the 43-year-old Lincoln Squ…
External link. Real Estate Trail does not republish source content.
More from the wire
Alexander & Baldwin lists Central Oahu shopping center for sale amid Hawaii retail boom
Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory dise…
Shorenstein Acquires 148 Lafayette Street in Manhattan's SoHo Neighborhood
Acquisition Marks Final Investment in Fund 14 and Reflects Continued Focus on High-Quality Office Properties with Strong Cash Flow and Rent Growth Potential SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Shorenstein Inv…